[go: up one dir, main page]

NO973659L - Use of LCK SH2-Specific Compounds for the Treatment of Autoimmune Diseases and Transplant Rejection - Google Patents

Use of LCK SH2-Specific Compounds for the Treatment of Autoimmune Diseases and Transplant Rejection

Info

Publication number
NO973659L
NO973659L NO973659A NO973659A NO973659L NO 973659 L NO973659 L NO 973659L NO 973659 A NO973659 A NO 973659A NO 973659 A NO973659 A NO 973659A NO 973659 L NO973659 L NO 973659L
Authority
NO
Norway
Prior art keywords
domain
human
autoimmune diseases
lck
treatment
Prior art date
Application number
NO973659A
Other languages
Norwegian (no)
Other versions
NO973659D0 (en
Inventor
Damien J Dunnington
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO973659D0 publication Critical patent/NO973659D0/en
Publication of NO973659L publication Critical patent/NO973659L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det beskrives en fremgangsmåte for behandling av autoimmunsykdommer i et individ, som omfatter at vedkommende individ administreres en terapeutisk effektiv mengde av en forbindelse som binder seg til et humant lek SH2 domene med en bindingsaffmitet som er mer enn 50 ganger høyere enn den bindingsaffinitet som forbindelsen binder seg til et humant src SH2 domene og et humant fyn SH2 domene med, og, binder seg til et humant hcp SH2 domene, et humant Grb2 SH2 domene, et humant SH-PTP2 SH2 domene og et humant p85 SH2 domene med en bindingsaffinitet som er mer enn 50 ganger lavere enn den bindingsaffinitet som forbindelsen binder seg til dette lek SH2 domenet med.There is disclosed a method of treating autoimmune diseases in a subject comprising administering to a subject a therapeutically effective amount of a compound that binds to a human play SH2 domain with a binding affinity greater than 50 times higher than the binding affinity to which the compound binds. attaches to a human src SH2 domain and a human fine SH2 domain with, and, binds to a human hcp SH2 domain, a human Grb2 SH2 domain, a human SH-PTP2 SH2 domain and a human p85 SH2 domain with a binding affinity that is more than 50 times lower than the binding affinity with which the compound binds to this play SH2 domain.

NO973659A 1995-02-10 1997-08-08 Use of LCK SH2-Specific Compounds for the Treatment of Autoimmune Diseases and Transplant Rejection NO973659L (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38638195A 1995-02-10 1995-02-10
US40022095A 1995-03-07 1995-03-07
US49735795A 1995-06-30 1995-06-30
PCT/US1996/001964 WO1996024343A1 (en) 1995-02-10 1996-02-09 Use of lck sh2 specific compounds to treat autoimmune diseases and allograft rejection

Publications (2)

Publication Number Publication Date
NO973659D0 NO973659D0 (en) 1997-08-08
NO973659L true NO973659L (en) 1997-10-08

Family

ID=27409758

Family Applications (1)

Application Number Title Priority Date Filing Date
NO973659A NO973659L (en) 1995-02-10 1997-08-08 Use of LCK SH2-Specific Compounds for the Treatment of Autoimmune Diseases and Transplant Rejection

Country Status (10)

Country Link
EP (2) EP0809490A4 (en)
JP (2) JPH10513474A (en)
KR (1) KR19980702115A (en)
AU (1) AU4923796A (en)
BR (1) BR9607614A (en)
CA (1) CA2212645A1 (en)
FI (1) FI973259A (en)
HU (1) HUP9802078A3 (en)
NO (1) NO973659L (en)
WO (1) WO1996024343A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922697A (en) * 1996-10-02 1999-07-13 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins
MXPA05010081A (en) 2003-03-24 2005-11-23 Hoffmann La Roche Benzyl-pyridazinons as reverse transcriptase inhibitors.
EP1730120A1 (en) 2004-03-23 2006-12-13 F.Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007913A1 (en) * 1992-09-25 1994-04-14 Warner-Lambert Company Peptide antagonists of sh2 binding and therapeutic uses thereof
US5580979A (en) * 1994-03-15 1996-12-03 Trustees Of Tufts University Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
US5710129A (en) * 1995-02-23 1998-01-20 Ariad Pharmaceuticals, Inc. Inhibitors of SH2-mediated processes

Also Published As

Publication number Publication date
JPH10513474A (en) 1998-12-22
FI973259A0 (en) 1997-08-07
NO973659D0 (en) 1997-08-08
JPH10513564A (en) 1998-12-22
EP0811159A1 (en) 1997-12-10
KR19980702115A (en) 1998-07-15
HUP9802078A3 (en) 1999-04-28
FI973259A (en) 1997-10-08
HUP9802078A2 (en) 1998-12-28
BR9607614A (en) 1998-06-09
CA2212645A1 (en) 1996-08-15
WO1996024343A1 (en) 1996-08-15
AU4923796A (en) 1996-08-27
EP0809490A4 (en) 1999-10-20
EP0809490A1 (en) 1997-12-03

Similar Documents

Publication Publication Date Title
AU5152293A (en) Treatment of autoimmune and inflammatory disorders
ATE247974T1 (en) COMBINATION THERAPY WITH A TNF-BINDING PROTEIN FOR THE TREATMENT OF DISEASES CAUSED BY TNF
NZ324500A (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
DK0975672T3 (en) Antibodies to inhibit blood coagulation and methods for its use
NO972972D0 (en) Compositions for the treatment of dermatological disorders and methods for their use
EP1245676A4 (en) Human monoclonal antibodies against tgf-beta ii receptor and medicinal use thereof
UA111707C2 (en) APPLICATION OF SELECTED HUMAN ANTIBODY ANTI-TNF-ALPHA
NO981436D0 (en) Pharmaceutical angiostatic dipeptide compositions and their use
NO963742D0 (en) Method of stimulating hematopoiesis with hemaglobin
ATE240395T1 (en) ANTIBODIES AGAINST E-SELECTIN
WO1999043353A3 (en) Combination anti-selectin and immunosuppressant therapy
AU7140596A (en) Specific binding members for human transforming growth factor beta; materials and methods
PT804252E (en) METALLIC CHELTER AGENTS THAT CONTAINS DIAMOND MONOAMINES AND THIOIS
DK0867184T3 (en) Use of tiagabine for the treatment of sleep disorders
CY1109817T1 (en) OLIGO-BETA (1,3) -GLUCAN AND MONOCLONIC ANTIBODIES AGAINST CANCER
NO20084032L (en) Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and their use as therapeutic agents
DE69426767D1 (en) Anti idiotypic antibodies to gonococci and methods and compositions using them.
KR960030947A (en) src Use of SH2-specific compounds for the treatment of bone resorption diseases
WO1999048489A3 (en) Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
CA2449488A1 (en) Compositions and methods for treating hyperimmune response in the eye
NO973659L (en) Use of LCK SH2-Specific Compounds for the Treatment of Autoimmune Diseases and Transplant Rejection
ATE442157T1 (en) USE OF ANTI-CD3 MONOCLONAL ANTIBODIES AND IL-5 FOR THE TREATMENT OF AUTOIMMUNE DISEASES
WO2002020619A3 (en) HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3)
EP0728482A3 (en) Use of hcp specific compounds to enhance erythropoiesis
ATE222768T1 (en) CTLA-8 IN COMBINATION WITH G-CSF OR WITH G-CSF AND IL-6, AND USE OF CTLA-8 TO TREAT INFECTIONS